Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of escalating doses of the novel PI3K
inhibitor WX-037 and to explore its effectiveness in combination with WX-554 which targets
mitogen activated protein kinase (MEK1 and MEK2). Preclinical evidence indicates that these
two novel compounds could provide targeted inhibition of both pathways to block tumour
growth.